SI-109, a peptide stemmed from the STAT3-binding motif of the protein gp130, was utilized to develop a peptide-based PROTAC termed as SD-36, which achieved potent STAT3 degradation and inhibited leukemia and lymphoma in vitro and in vivo [57]. This evidence concerns the gene STAT3 and lymphoma.